FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology and immunology, particularly to antibodies to HIV proteins, and represents a chimeric (mouse-human) monoclonal antibody effectively binding the p17 matrix protein of human immunodeficiency virus of the first subtype A type.
EFFECT: invention can be effectively used for prevention and therapy of HIV infection.
1 cl, 2 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
| METHOD OF CONTROL OF HEART RHYTHM AND REDUCTION OF INDIVIDUAL CARDIOMYOCYTES USING THERMOGENETICS | 2022 |
|
RU2802995C1 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
| METHOD OF PRODUCING PRECURSOR RENAL CELLS | 2016 |
|
RU2730861C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
